Second quarter 2022 revenue increased 35% YoY and 42% sequentially to $561 Thousand
Company sees growth in its branded consumer products and launches MEDAGEL Pro Pads
LANGHORNE, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the second quarter ended June 30, 2022.
Adam Levy, NEXGEL Chief Executive Officer, commented, “During the second quarter of 2022, we successfully continued to grow revenue year-over-year. I am particularly pleased with our ability to generate positive gross profit during the quarter and, from an operating perspective, we increased our investment in R&D for the long-term growth opportunities of the business. Our growth is attributable to our branded products and contract manufacturing segments. Within the branded product segment, we are focused on expanding our hydrogel line and recently introduced our 11th product in July, MEDAGEL Pro Pads. We also saw increased demand within our contract manufacturing business, which continues to advance as a result of sustained use in our customers' line extensions. We are moving forward with our plan to advance NEXDrape, our first potential medical device product, and expect clinical data before the end of the year. As of June 30, 2022, we had $9.7 million of cash and cash equivalents, including our investment in treasuries of $5.4 million, which we believe provides us with a very comfortable balance sheet to continue our planned year-over-year growth the foreseeable future and invest in the business.”
Second Quarter 2022 Financial Highlights
Revenue for the three months ended June 30, 2022 was $561 thousand, an increase of 35%, when compared to $417 thousand for the three months ended June 30, 2021, and a sequential increase of 42% as compared to $396 thousand for the first quarter ended March 30, 2022. The increase in our overall revenue was due to sales growth of new products as well as our initiatives in branded consumer products.
Gross profit was $101 thousand, yielding a 18% gross profit margin, for the three months ended June 30, 2022, as compared to a gross profit of $4 thousand for the three months ended June 30, 2021.
Cost of revenues was $460 thousand for the three months ended June 30, 2022, as compared to $413 thousand for the three months ended June 30, 2021. The increase in cost of revenues is primarily aligned with the increase in revenues in the current year.
Operating expenses, including R&D and SG&A expenses, increased by $262 thousand to $819 thousand for the three months ended June 30, 2022, as compared to $557 thousand for the three months June 30, 2021. During the quarter R&D totaled $111 thousand as compared to $10 thousand during the second quarter of 2021 and $24 thousand during the first quarter of 2022. The increase in SG&A expenses is primarily attributable to increases in compensation and benefits and costs for professional fees and other administrative expenses associated with public company governance requirements.
As of June 30, 2022, NEXGEL had $9.7 million of cash and cash equivalents, which includes an investment in treasuries of $5.4 million.
Second Quarter 2022 Operational Highlights
Launched MEDAGEL Hydroliner Pro Pads. The MEDAGEL Pro Pads are for protecting eyelashes during cosmetic extension and lift and tint services. These under-eye pads provide powerful, yet skin-friendly adhesion aimed at isolating the lower lashes.
Conference Call Details
Management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its quarterly operational and financial results for the second quarter 2022.
NEXGEL Second Quarter 2022 Results Conference Call
Date: August 10, 2022
Time: 4:30 P.M. ET
Live Call: +1-877-407-9208 (U.S. Toll Free) or +1-201-493-6784 (International)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1562627&tp_key=63fb56d71d
For interested individuals unable to join the conference call, a replay will be available through August 17, 2022, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13732071. An archived version of the webcast will also be available on NEXGEL’s Investor Relations site: https://ir.nexgel.com/.
About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons including the impact of the COVID-19 pandemic. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2021, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
valter@kcsa.com
Media Contacts:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
ckasunich@kcsa.com / rcona@kcsa.com
NEXGEL, INC
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 2022 AND DECEMBER 31, 2021
(Unaudited)
(in thousands, except share and per share data)
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| ASSETS: | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 4,420 | $ | 13,350 | ||||
| Marketable securities | 5,371 | - | ||||||
| Accounts receivable, net | 300 | 209 | ||||||
| Inventory | 381 | 291 | ||||||
| Prepaid expenses and other current assets | 313 | 77 | ||||||
| Total current assets | 10,785 | 13,927 | ||||||
| Goodwill | 311 | 311 | ||||||
| Intangibles, net | 26 | 33 | ||||||
| Property and equipment, net | 704 | 723 | ||||||
| Operating lease - right of use asset | 1,832 | 1,926 | ||||||
| Other assets | 113 | 63 | ||||||
| Total assets | $ | 13,771 | $ | 16,983 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 522 | $ | 254 | ||||
| Accrued expenses and other current liabilities | 85 | 62 | ||||||
| Convertible notes payable | 1,240 | 2,037 | ||||||
| Note payable, current portion | 18 | 10 | ||||||
| Warrant liability | 419 | 318 | ||||||
| Operating lease liability, current portion | 207 | 207 | ||||||
| Total current liabilities | 2,491 | 2,888 | ||||||
| Long-Term Liabilities: | ||||||||
| Operating lease liability, net of current portion | 1,669 | 1,744 | ||||||
| Notes payable, net of current portion | 263 | 266 | ||||||
| Total long-term liabilities | 1,932 | 2,010 | ||||||
| Total liabilities | 4,423 | 4,898 | ||||||
| Commitments and Contingencies (Note 14) | ||||||||
| Preferred Stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding | - | - | ||||||
| Common Stock, par value $0.001 per share, 750,000,000 shares authorized; 5,572,234 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | 6 | 6 | ||||||
| Additional paid-in capital | 19,025 | 18,891 | ||||||
| Accumulated deficit | (9,683 | ) | (6,812 | ) | ||||
| Total stockholders’ equity | 9,348 | 12,085 | ||||||
| Total liabilities and stockholders’ equity | $ | 13,771 | $ | 16,983 | ||||
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(Unaudited)
(in thousands, except share and per share data)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues, net | $ | 561 | $ | 417 | $ | 956 | $ | 683 | ||||||||
| Cost of revenues | 460 | 413 | 884 | 722 | ||||||||||||
| Gross (loss)/profit | 101 | 4 | 72 | (39 | ) | |||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 111 | 10 | 135 | 17 | ||||||||||||
| Selling, general and administrative | 708 | 547 | 1,467 | 1,017 | ||||||||||||
| Total operating expenses | 819 | 557 | 1,602 | 1,034 | ||||||||||||
| Loss from operations | (718 | ) | (553 | ) | (1,530 | ) | (1,073 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest expense | (348 | ) | (370 | ) | (1,092 | ) | (518 | ) | ||||||||
| Loss on debt extinguishment | — | — | (150 | ) | (25 | ) | ||||||||||
| Debt discount costs | — | (52 | ) | — | (68 | ) | ||||||||||
| Other income | 2 | 147 | 2 | 147 | ||||||||||||
| Changes in fair value of warrant liability | 29 | 2 | (101 | ) | 8 | |||||||||||
| Total other income (expense) | (317 | ) | (273 | ) | (1,341 | ) | (456 | ) | ||||||||
| Loss before income taxes | (1,035 | ) | (826 | ) | (2,871 | ) | (1,529 | ) | ||||||||
| Income tax expense | — | — | — | — | ||||||||||||
| Net loss | $ | (1,035 | ) | $ | (826 | ) | (2,871 | ) | (1,529 | ) | ||||||
| Net loss per common share - basic | $ | (0.19 | ) | $ | (0.28 | ) | (0.52 | ) | (0.52 | ) | ||||||
| Net loss per common share - diluted | $ | (0.19 | ) | $ | (0.28 | ) | (0.52 | ) | (0.52 | ) | ||||||
| Weighted average shares used in computing net loss per common share - basic | 5,572,234 | 2,939,837 | 5,572,234 | 2,918,759 | ||||||||||||
| Weighted average shares used in computing net loss per common share – diluted | 5,572,234 | 2,939,837 | 5,572,234 | 2,918,759 | ||||||||||||
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(Unaudited)
(in thousands, except share data)
| Common Stock | Additional Paid-in | Retained Earnings (Accumulated | Total Stockholders’ | |||||||||||||||||
| Shares | Amount | Capital | Deficit) | Equity (Deficit) | ||||||||||||||||
| Balance, January 1, 2022 | 5,572,234 | $ | 6 | $ | 18,891 | $ | (6,812 | ) | $ | 12,085 | ||||||||||
| Stock-based compensation | - | - | 55 | - | 55 | |||||||||||||||
| Net loss | - | - | - | (1,836 | ) | (1,836 | ) | |||||||||||||
| Balance, March 31, 2022 | 5,572,234 | $ | 6 | $ | 18,946 | $ | (8,648 | ) | $ | 10,304 | ||||||||||
| Stock-based compensation | - | - | 54 | - | 54 | |||||||||||||||
| Restricted stock vesting | - | - | 25 | - | 25 | |||||||||||||||
| Net loss | - | - | - | (1,035 | ) | (1,035 | ) | |||||||||||||
| Balance, June 30, 2022 | 5,572,234 | $ | 6 | $ | 19,025 | $ | (9,683 | ) | $ | 9,348 | ||||||||||
| Common Stock | Additional Paid-in | Retained Earnings (Accumulated | Total Stockholders’ | |||||||||||||||||
| Shares | Amount | Capital | Deficit) | Equity (Deficit) | ||||||||||||||||
| Balance, January 1, 2021 | 2,838,047 | $ | 3 | $ | 2,570 | $ | (2,502 | ) | $ | 71 | ||||||||||
| Stock-based compensation | - | - | 69 | - | 69 | |||||||||||||||
| Restricted stock vesting | - | - | 21 | - | 21 | |||||||||||||||
| Issuances of common stock, net of issuance costs | 101,800 | - | 285 | - | 285 | |||||||||||||||
| Warrants issued for debt issuance | - | - | (18 | ) | - | (18 | ) | |||||||||||||
| Beneficial conversion and warrant features of convertible debt | - | - | 1,276 | - | 1,276 | |||||||||||||||
| Net loss | - | - | - | (704 | ) | (704 | ) | |||||||||||||
| Balance, March 31, 2021 | 2,939,847 | $ | 3 | $ | 4,203 | $ | (3,206 | ) | $ | 1,000 | ||||||||||
| Stock-based compensation | - | - | 74 | - | 74 | |||||||||||||||
| Restricted stock vesting | 39,324 | - | 21 | - | 21 | |||||||||||||||
| Net loss | - | - | - | (826 | ) | (826 | ) | |||||||||||||
| Balance, June 30, 2021 | 2,979,171 | $ | 3 | $ | 4,298 | $ | (4,032 | ) | $ | 269 | ||||||||||
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(Unaudited)
(in thousands)
| Six Months Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Operating Activities | ||||||||
| Net loss | $ | (2,871 | ) | $ | (1,529 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 57 | 56 | ||||||
| Changes in ROU asset and operating lease liability | 19 | 6 | ||||||
| Share-based compensation | 134 | 185 | ||||||
| Changes in fair value of warrant liability | 101 | (8 | ) | |||||
| Amortization of deferred financing costs | 1,086 | 528 | ||||||
| Loss on extinguishment of debt | 150 | 24 | ||||||
| Forgiveness of debt | - | (148 | ) | |||||
| Beneficial conversion feature in excess of face value | - | 51 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (91 | ) | (146 | ) | ||||
| Inventory | (90 | ) | 7 | |||||
| Prepaid expenses and other assets | (286 | ) | 61 | |||||
| Accounts payable | 268 | (67 | ) | |||||
| Accrued expenses and other liabilities | 28 | (15 | ) | |||||
| Deferred revenue | - | (38 | ) | |||||
| Net Cash Used in Operating Activities | (1,495 | ) | (1,033 | ) | ||||
| Investing Activities | ||||||||
| Investment in marketable securities | (5,371 | ) | - | |||||
| Capital expenditures | (31 | ) | (267 | ) | ||||
| Net Cash Used in Investing Activities | (5,402 | ) | (267 | ) | ||||
| Financing Activities | ||||||||
| Issuance of common stock, net of issuance costs | - | 285 | ||||||
| Proceeds from notes payable | - | 15 | ||||||
| Principle payment of notes payable | (2,033 | ) | (15 | ) | ||||
| Proceeds from notes payable (PPP) | - | 128 | ||||||
| Proceeds from convertible notes | - | 1,337 | ||||||
| Principal payment on convertible notes | - | (100 | ) | |||||
| Net Cash Provided by (Used In) Financing Activities | (2,033 | ) | 1,650 | |||||
| Net Increase (Decrease) in Cash and Cash Equivalents | (8,930 | ) | 350 | |||||
| Cash and Cash Equivalents – Beginning of period | 13,350 | 32 | ||||||
| Cash and Cash Equivalents – End of period | $ | 4,420 | $ | 382 | ||||
| Supplemental Disclosure of Cash Flows Information | ||||||||
| Cash paid during the year for: | ||||||||
| Interest | - | - | ||||||
| Taxes | - | - | ||||||
| Supplemental Non-cash Investing and Financing activities | ||||||||
| Fair value of beneficial conversion and warrant features of Convertible Notes Payable | $ | - | $ | 1,276 | ||||
| Original issue discounts recognized on Convertible Notes Payable | $ | - | $ | 343 | ||||
| Warrants issued for debt and equity financing costs | $ | - | $ | 130 | ||||
